Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.

ABSTRACT:

Background

Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents.

Material and methods

Discovery cohort consisted of patients who were treated with anti-programmed cell death protein-1 (PD-1) agents for advanced melanoma (MEL), non-small cell lung cancer (NSCLC) or renal and bladder cancers (GU) at Oulu University Hospital and had pretreatment C reactive protein (CRP), or neutrophil/lymphocyte values available. As a validation cohort, we collected patients treated with anti-PD-1 agents from three other hospitals in Finland.

Results

In the discovery cohort (n=

SUBMITTER: Iivanainen S 

PROVIDER: S-EPMC6735669 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature